On Physician-Industry Relationships and Unreasonable Standards of Proof for Harm: A Population-Level Bioethics Approach

Kennedy Inst Ethics J. 2016 Jun;26(2):173-94. doi: 10.1353/ken.2016.0022.

Abstract

The primary claim of this paper is that a widely used argument against obstructing, curtailing, or eliminating deep physician-industry relationships is deficient. The typical argument critiqued requires that proof that physician-industry relationships cause harm flows from randomized controlled trials. Chief among the deficiencies in this claim is the fact that this specific demand for proof of harm essentially guts the precautionary principle. In so doing, the typical argument neuters the basic justification for public health action. In place of this fallacious move, the paper argues that proof of harm can be demonstrated via evidentiary standards widely accepted within the knowledge communities of public health scientists and epidemiologists. The paper concludes by noting that while there may be good reasons to oppose curtailment of deep physician-industry relationships, the typical argument described here is not among them.

MeSH terms

  • Beneficence
  • Bioethical Issues
  • Causality*
  • Conflict of Interest*
  • Dissent and Disputes
  • Drug Industry* / ethics
  • Drug Industry* / legislation & jurisprudence
  • Drug Prescriptions* / economics
  • Drug Prescriptions* / standards
  • Epidemiologic Studies*
  • Ethical Analysis
  • Ethical Theory
  • Evidence-Based Medicine* / methods
  • Evidence-Based Medicine* / standards
  • Health Policy* / legislation & jurisprudence
  • Health Policy* / trends
  • Humans
  • Numbers Needed To Treat*
  • Physicians / ethics*
  • Physicians / legislation & jurisprudence
  • Public Health* / ethics
  • Randomized Controlled Trials as Topic
  • United States